Ellume Gets $231.8 Million from DOD to Increase At-Home COVID-19 Test Production
The U.S. Department of Defense (DOD) has granted Ellume $231.8 million to bolster American manufacturing capacity for its at-home COVID-19 test, funding that will allow the Australian company to make hundreds of thousands of more tests daily by the end of the year.
The government funding will enable the digital diagnostics maker to drastically increase its production capabilities and manufacture an additional 640,000 Ellume COVID-19 Home Tests per day by December 2021 for use in the U.S. The arrangement also procures 8.5 million tests that will be distributed across the country as part of the government’s pandemic response.
The company’s home test is the first fully at-home diagnostic to receive FDA Emergency Use Authorization (EUA) for detecting COVID-19 in both symptomatic and asymptomatic patients. It delivers results via a smart phone app in approximately 15 minutes using a nasal swab specimen.